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Abstract
Background: The influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for
hepatocellular carcinoma (HCC) remains a matter of debate. This study is a meta-analysis of the available evidence.
Methods: A literature search was performed to identify comparative studies reporting postoperative survival of
HCC in different types of viral hepatitis. Pooled odds ratios (OR) and weighted mean differences (WMD with 95%
confidence intervals (95% CI) were calculated using either the fixed effects model or random effects model.
Results: Twenty studies matched the selection criteria and reported on 4744 subjects, of whom 2008 in the HBV-
positive (B-HCC) group, 2222 in the HCV-positive (C-HCC) group, and 514 in the hepatitis B- and C-negative (NBNC-
HCC). Meta-analysis showed that patients with HBV or HCV infection had a worse 5-year disease-free survival when
compared to patients with NBNC-HCC (respectively: OR: 0.39, 95% CI: 0.28 to 0.53, P < 0.001; WMD: 0.37, 95% CI: 0.22 to
0.64, P < 0.001). There was a tendency toward higher 5-year overall survival rates in the NBNC-HCC group compared to
those in the other two groups, although these differences were not statistically significant. Both the 5-year overall
survival and disease-free survival were not different among the B-HCC and C-HCC groups.
Conclusions: Patients with positive serology for hepatitis B or C undergoing resection for HCC had a poor
prognosis compared to patients with negative serology.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in the world, responsible for 500,000 deaths
globally every year [1]. Chronic viral hepatitis and liver
cirrhosis related to hepatitis B virus (HBV) and hepatitis
C virus (HCV) infections represent the major known
risk factors for HCC. A review of the literature reveals
that 75% to 80% of cases of HCC are attributable to per-
sistent viral infections with either HBV (50%-55%) or
HCV (25%-30%) [2]. Nevertheless, some patients with
HCC are dually infected, whereas others are negative for
both HBV and HCV [3-7].
Hepatic resection is widely accepted as the treatment
of choice for HCC. With regard to surgery, it is impor-
tant to determine whether or not the prognosis after
resection differ according to the viral status. So far, the
influence of viral status on prognosis for patients with
HCC treated by resection remains controversial. For
example, Yamanaka et al. [3] reported that the disease-
free and overall survival rates of hepatitis B- and C-
negative group were better than those of viral infections
groups. In contrast, Pawlik et al. [5] reported that the
presence of viral hepatitis did not significantly affect the
survival rate.
Meta-analysis can be used to evaluate the existing lit-
erature in both a qualitative and quantitative way by
comparing and integrating the results of different studies
and taking into account variations in characteristics that
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interest [8]. This study uses metaanalytical techniques to
evaluate the influence of viral hepatitis status on prog-
nosis in patients with HCC treated by surgery.
Methods
Study Selection
Infection with HBV was defined as positivity for hepatitis
B surface antigen (HBsAg) or for anti-hepatitis B core
antibody. Infection with HCV was defined as positivity for
serum anti-HCV antibody (HBcAb). Therefore, patients
were divided into four groups: HBV-positive (B-HCC),
HCV-positive (C-HCC), dual hepatitis B- and C positive
(BC-HCC), and hepatitis B- and C-negative (NBNC-
HCC). A MEDLINE, EMBASE, OVID, and Cochrane
database search was performed on all studies reporting
postoperative survival between four groups. The following
Mesh search headings were used: “hepatitis B virus,”
“hepatitis C virus,”“ hepatocellular carcinoma,”“ survival
rate,”“ liver resection,” and “hepatectomy”. Only studies on
humans and in English language were considered for
inclusion. Reference lists of all retrieved articles were man-
ual searched for additional studies.
Data Extraction
Two reviewers (LW and XS, respectively) independently
extracted the following parameters from each study: first
author, year of publication, study population characteris-
tics, study design, inclusion and exclusion criteria, num-
ber of patients with different preoperative viral status,
male: female ratio. All relevant text, tables and figures
were reviewed for data extraction. Discrepancies between
the two reviewers were resolved by discussion and
consensus.
Criteria for Inclusion and Exclusion
For inclusion in the meta-analysis, a study had to fulfill
the following criteria: 1) evaluate the influence of viral
hepatitis status on prognosis in HCC patients undergoing
hepatic resection; 2) report on at least one of the out-
come measures mentioned below; 3) In dual (or multiple)
studies were reported by the same institution and/or
authors, either the one of higher quality or the most
recent publication was included in the analysis.
Abstracts, letters, editorials and expert opinions, reviews
without original data, case reports and studies lacking con-
trol groups were excluded. The following studies were also
excluded: 1) those with no clearly reported outcomes of
interest; 2) those evaluating patients with other types of
malignant liver tumors and did not contain a distinct
group of patients with HCC; or (3) those including
patients undergoing palliative treatment (noncurative sur-
gical intent).
Outcomes of Interest
Primary outcomes of interest were 5-year overall and
disease-free survival after resection. Secondary outcomes
of interest were clinicopathologic features.
Statistical Methods
The meta-analysis was performed using the Review Man-
ager (RevMan) software, version 4.2.7 (The Cochrane
Collaboration, Software Update, Oxford). We analysed
dichotomous variables using estimation of odds ratios
(OR) with a 95% confidence interval (95% CI), and con-
tinuous variables using weighted mean difference
(WMD) with a 95% CI. The overall effect was tested
using Z scores, with significance being set at P < 0.05.
Pooled effect was calculated using either the fixed effects
model or random effects model. Heterogeneity was eval-
uated by c
2 and I
2. In the absence of statistically signifi-
cant heterogeneity, the fixed-effect method was used to
combine the results. When heterogeneity was confirmed
(P ≤ 0.10), the random-effect method was used [9].
Results
Selection of Studies
The search strategy initially generated 38 studies
[3-7,10-42]. Of these studies, 18 were excluded for var-
ious reasons: 11 including patients with unresectable
lesions [6,7,10-18], four without survival information
[19-21]. Three were published by the same team with
overlapping study populations [23-25]. Finally, a total of
20 studies published between 1995 and 2011 matched
the inclusion criteria and were therefore included
[3-5,27-42].
The patients with BC-HCC were too small in number
and so were not separately analyzed in many studies. Only
seven of 20 studies reported 186 cases of such patients in
current review [3-5,27-29]. To avoid high bias-risk of pub-
lication, we did not perform an analysis of BC-HCC
group. Therefore, 4744 patients were included in the
meta-analysis, of whom 2008 in the B-HCC group, 2222
in the C-HCC group, and 514 in the NBNC-HCC group.
The median or mean (range) duration for the entire
cohort of patients in 11 studies providing data on follow-
up ranged from 20.3 to 132 months. In two manuscripts,
Ahmad et al. [35] and Sasaki et al. [40] reported the data
of subsets of patients. The characteristics of these 20 stu-
dies are summarized in Table 1.
Patients Characteristics
Results from overall meta-analysis are outlined in Table 2.
The mean age of patients in the B-HCC group was
significantly younger than that of both the C-HCC
(WMD: -10.11, 95% CI: -11.14 to -9.09, P <0 . 0 0 1 )a n d
the NBNC-HCC groups (WMD: -10.42, 95% CI: -12.72
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Page 2 of 10Table 1 Baseline characteristics of studies included in the meta-analysis
Author Year Country Group No. of
patients
Male/
Female
Mean age
(years)
Mean follow-up
(months)
Takenaka [30] 1995 Japan B-HCC
C-HCC
30
96
22/8
77/19
57.0 ± 9.4
61.7 ± 6.9
–
–
Miyagawa [31] 1996 Japan B-HCC
C-HCC
NBNC
32
124
19
21/11
96/28
15/4
52.1 ± 12.4
63.9 ± 7.0
62.2 ± 11.8
–
–
–
Yamanaka [3] 1997 Japan B-HCC
C-HCC
NBNC
27
151
20
24/3
125/26
18/2
51 ± 10
63 ± 6.3
63 ± 6.4
–
–
–
Wu [26] 1999 Taiwan B-HCC
C-HCC
NBNC
131
70
40
110/21
56/14
29/11
54.3 ± 1.1
64.1 ± 1.1
68.9 ± 1.9
34.5*&
Shiraishi [32] 1999 Japan B-HCC
C-HCC
NBNC
11
21
12
–
–
–
54.0 ± 3.2
62.0 ± 1.8
63.0 ± 4.1
–
–
–
Lee [4] 2000 Taiwan B-HCC
C-HCC
NBNC
133
66
30
112/21
48/18
20/10
49.4 ± 12.7
61.7 ± 9.2
54.3 ± 13.3
23.5 ± 16.3 &
Noguchi [33] 2000 Japan B-HCC
C-HCC
NBNC
44
232
13
34/10
172/60
12/1
51.6 ± 8.4
65.0 ± 7.0
60.9 ± 6.7
–
–
–
Roayaie [34] 2000 United States B-HCC
C-HCC
21
24
10/11
17/7
54.3 ± 15.3
63.4 ± 8.5
20.3*&
Ahmad [35] 2001 United States B-HCC
C-HCC
NBNC
18
44
15
13/5
34/10
6/9
60
61
63
30*
27*
33*
Chen [36] 2001 Taiwan B-HCC
C-HCC
211
59
190/21
47/12
57.6 ± 12.7
66.9 ± 8.2
–
–
Wakai [37] 2003 Japan B-HCC
C-HCC
NBNC
32
55
24
20/12
46/9
18
52.5 (16-77)*
64 (46-78)
68 (45-79)
75*&
Pawlik [5] 2004 Multi center B-HCC
C-HCC
NBNC
163
79
126
137/26
48/31
90/36
60*
60
51
33*&
Uchiyama [39] 2005 Japan B-HCC
C-HCC
NBNC
25
72
24
18/7
48/24
18/6
54 ± 10
64 ± 9
65 ± 8
–
–
–
Yokoi [38] 2005 Japan B-HCC
C-HCC
NBNC
25
116
13
19/6
95/21
10/3
57 (32-74)*
64 (46-85)
58 (28-72)
–
–
–
Sasaki [40] 2006 Japan. B-HCC
C-HCC
66
351
49/17
268/83
>6 5( n=5 )
> 65 (n = 114)
132*
121.2*
Li [27] 2007 China B-HCC
C-HCC
NBNC
251
75
54
212/39
62/13
44/10
51.2 ± 4.2
63.2 ± 7.3
67.1 ± 5.7
48.3* &
Nanashima [28] 2007 Japan B-HCC
C-HCC
NBNC
76
124
29
61/15
99/25
21/8
59 ± 11
67 ± 7
65 ± 8
–
–
–
Kondo [41] 2008 Japan B-HCC
C-HCC
NBNC
78
127
60
58/20
94/33
43/17
54.7 ± 11.6
67.2 ± 6.7
67.9 ± 10.3
26*&
Cescon [29] 2009 Italy B-HCC
C-HCC
NBNC
25
130
35
24/1
90/40
30/5
60.2 ± 9.8
65.2 ± 8.1
64.2 ± 9.1
30*&
Kao [42] 2011 Taiwan B-HCC
C-HCC
609
206
516/93
147/59
56.3 ± 13.5
67.2 ± 9.1
40.6*&
HCC = hepatocellular carcinoma; B-HCC = hepatitis B-related hepatocellular carcinoma; C-HCC = hepatitis C-related hepatocellular carcinoma; NBNC-HCC = no
infection of HBV or HCV related hepatocellular carcinoma; * = median; & = entire group.
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Outcome of interest No. of studies No.of
patients
Results OR/WMD 95% CI P-value I
2 (%)
Patients characteristics
Age (years)
B-HCC versus C-HCC 15 [3,4,26-34,36,39,41,42] 3281 B-HCC = 54.4 ± 9.2, C-HCC = 64.3 ± 6.8 -10.11 -11.14, -9.09 < 0.001 65.3
B-HCC versus NBNC-HCC 11 [3,4,26,27,29,31-33,39,41] 1169 B-HCC = 53.7 ± 8.5, NBNC-HCC = 63.7 ± 7.7 -10.42 -12.72, -8.12 < 0.001 86.1
C-HCC versus NBNC-HCC 11 [3,4,26,27,29,31-33,39,41] 1528 C-HCC = 64.2 ± 6.4, NBNC-HCC = 63.7 ± 7.7 0.08 -2.18, 2.38 0.95 88.2
Male
B-HCC versus C-HCC 19 [3-5,26-31,33-42] 4198 B-HCC = 82.6%, C-HCC = 75.8% 1.19 0.89, 1.60 0.24 61.2
B-HCC versus NBNC-HCC 14 [3-5,26-29,31,33,35,37-39,41] 1562 B-HCC = 81.4%, NBNC-HCC = 74.5% 1.43 1.10, 1.86 0.008 16.3
C-HCC versus NBNC-HCC 14 [3-5,26-29,31,33,35,37-39,41] 1967 C-HCC = 75.9%, NBNC-HCC = 74.5% 0.96 0.74, 1.23 0.74 31
Liver function
Serum ALT level (IU/l)
B-HCC versus C-HCC 11 [3,4,27,29,30,32-34,36,39,41] 1909 B-HCC = 56.4 ± 44.8, C-HCC = 76.9 ± 47.6 -16.84 -21.02, -12.65 < 0.001 23.4
B-HCC versus NBNC-HCC 8 [3,4,27,29,32,33,39,41] 842 B-HCC = 56.7 ± 55.9, NBNC-HCC = 39.6 ± 31.1 15.30 4.59, 26.01 0.005 73.9
C-HCC versus NBNC-HCC 8 [3,4,27,29,32,33,39,41] 1122 C-HCC = 74.1 ± 43.8, NBNC-HCC = 39.6 ± 31.1 34.41 23.75, 45.08 < 0.001 84.9
Serum AST level (IU/l)
B-HCC versus C-HCC 8 [3,4,29,30,32,33,39,41] 842 B-HCC = 60.0 ± 56.7, C-HCC = 70.8 ± 38.1 -13.17 -22.29, -4.05 0.005 61.5
B-HCC versus NBNC-HCC 7 [3,4,29,32,33,39,41] 537 B-HCC = 61.0 ± 55.9, NBNC-HCC = 43.8 ± 25.5 13.06 0.13, 26.00 0.05 72.8
C-HCC versus NBNC-HCC 7 [3,4,29,32,33,39,41] 993 C-HCC = 69.9 ± 37.7, NBNC-HCC = 43.8 ± 25.5 24.87 18.94, 30.79 < 0.001 56.5
Serum albumin level (g/dl)
B-HCC versus C-HCC 10 [3,27,29-31,33,34,36,39,41] 1834 B-HCC = 3.93 ± 0.48, C-HCC = 3.69 ± 0.48 0.23 0.08, 0.38 0.002 87.4
B-HCC versus NBNC-HCC 7 [3,27,29,31,33,39,41] 707 B-HCC = 3.91 ± 0.45, NBNC-HCC = 3.94 ± 0.48 -0.07 -0.15, 0.00 0.07 36.4
C-HCC versus NBNC-HCC 7 [3,27,29,31,33,39,41] 1136 C-HCC = 3.61 ± 0.47, NBNC-HCC = 3.94 ± 0.48 -0.29 -0.53, -0.05 0.002 89.7
ICG R15 (%)
B-HCC versus C-HCC 10 [3,4,26,31-33,36,39,41] 1740 B-HCC = 12.9 ± 7.8, C-HCC = 20.4 ± 9.1 -6.58 -8.3, -4.87 < 0.001 78.9
B-HCC versus NBNC-HCC 8 [3,4,26,31-33,39,41] 699 B-HCC = 12.8 ± 7.5, NBNC-HCC = 13.9 ± 7.7 -0.74 -1.77, -0.30 0.16 21.3
C-HCC versus NBNC-HCC 8 [3,4,26,31-33,39,41] 1081 C-HCC = 21.0 ± 9.0, NBNC-HCC = 13.9 ± 7.7 5.92 3.85, 7.99 < 0.001 74.3
Child’s grade A
B-HCC versus C-HCC 9 [4,5,27,28,32,35,38,40,42] 2434 B-HCC = 88.3%, C-HCC = 80.8% 1.68 1.25, 2.25 < 0.001 34.9
B-HCC versus NBNC-HCC 7 [4,5,27,28,32,35,38] 956 B-HCC = 79.4%, NBNC-HCC = 80.6% 1.31 0.87, 1.98 0.20 0
C-HCC versus NBNC-HCC 7 [4,5,27,28,32,35,38] 804 C-HCC = 78.4%, NBNC-HCC = 80.6% 0.69 0.46, 1.05 0.08 1.1
Serum T-Bil level (mg/dL)
B-HCC versus C-HCC 9 [4,27,29-31,33,36,39,41] 1579 B-HCC = 0.91 ± 0.47, C-HCC = 1.23 ± 0.83 -0.14 -0.27, -0.01 0.03 80.1
B-HCC versus NBNC-HCC 6 [4,27,29,31,39,41] 766 B-HCC = 0.92 ± 0.47, NBNC-HCC = 0.87 ± 0.49 0.06 -0.16, 0.28 0.60 90.3
C-HCC versus NBNC-HCC 6 [4,27,29,31,39,41] 816 C-HCC = 1.18 ± 0.76, NBNC-HCC = 0.87 ± 0.49 0.25 -0.02, 0.52 0.07 90.6
Serum platelet count (×10
3/mm)
B-HCC versus C-HCC 7 [27,29,30,33,34,39,41] 1230 B-HCC = 166.6 ± 85.0, C-HCC = 137.5 ± 66.9 24.47 1.24, 47.7 0.04 82.1
B-HCC versus NBNC-HCC 5 [27,29,33,39,41] 609 B-HCC = 156.8 ± 73.4, NBNC-HCC = 192.2 ± 72.4 -28.88 -41.93, -15.83 < 0.001 30.9
Z
h
o
u
e
t
a
l
.
W
o
r
l
d
J
o
u
r
n
a
l
o
f
S
u
r
g
i
c
a
l
O
n
c
o
l
o
g
y
2
0
1
1
,
9
:
1
0
8
h
t
t
p
:
/
/
w
w
w
.
w
j
s
o
.
c
o
m
/
c
o
n
t
e
n
t
/
9
/
1
/
1
0
8
P
a
g
e
4
o
f
1
0Table 2 Results of a meta-analysis (Continued)
C-HCC versus NBNC-HCC 5 [27,29,33,39,41] 822 C-HCC = 138.2 ± 66.6, NBNC-HCC = 192.2 ± 72.4 -50.43 -75.13, -25.72 < 0.001 74.8
Tumor characteristics
Size (cm)
B-HCC versus C-HCC 10 [3,26,27,29,30,33,34,36,39,41] 1879 B-HCC = 5.4 ± 2.5, C-HCC = 4.0 ± 2.1 1.32 0.38, 2.27 0.006 98.4
B-HCC versus NBNC-HCC 7 [3,26,27,29,33,39,41] 827 B-HCC = 5.1 ± 2.5, NBNC-HCC = 5.3 ± 2.6 -0.02 -0.94, 0.00 0.97 96.5
C-HCC versus NBNC-HCC 7 [3,26,27,29,33,39,41] 1103 C-HCC = 3.8 ± 2.2, NBNC-HCC = 5.3 ± 2.6 -0.86 -1.27, -0.45 < 0.001 78.1
Coexisting cirrhosis
B-HCC versus C-HCC 15 [3,4,26-32,34-38,40-42] 3623 B-HCC = 53.4%, C-HCC = 65.7% 0.71 0.54, 0.92 0.01 55.5
B-HCC versus NBNC-HCC 12 [3,4,26-29,31,32,35,37,38,41] 1190 B-HCC = 61.8%, NBNC-HCC = 45.5% 2.61 1.56, 4.64 < 0.001 63.1
C-HCC versus NBNC-HCC 12 [3,4,26-29,31,32,35,37,38,41] 1454 C-HCC = 69.9%, NBNC-HCC = 45.5% 3.92 2.35, 6.53 < 0.001 56.4
Vascular invasion
B-HCC versus C-HCC 17 [3-5,26-30,34-42] 3760 B-HCC = 46.2%, C-HCC = 34.4% 1.29 0.97, 1.73 0.08 61.2
B-HCC versus NBNC-HCC 12 [3-5,26-29,35,37-39,42] 1454 B-HCC = 31.9%, NBNC-HCC = 32.9% 1.44 0.99, 2.11 0.06 37.5
C-HCC versus NBNC-HCC 12 [3-5,26-29,35,37-39,42] 1579 C-HCC = 28.7%, NBNC-HCC = 32.9% 0.99 0.62, 1.56 0.96 59.0
Intrahepatic metastases/satellite nodules
B-HCC versus C-HCC 11 [4,26,28-31,35,37-40] 1836 B-HCC = 31%, C-HCC = 24.5% 1.23 0.87, 1.73 0.24 42.0
B-HCC versus NBNC-HCC 9 [4,26,28,29,31,35,37-39] 726 B-HCC = 30.3%, NBNC-HCC = 28.8% 1.01 0.56, 1.83 0.97 49.9
C-HCC versus NBNC-HCC 9 [4,26,28,29,31,35,37-39] 1030 C-HCC = 24.4%, NBNC-HCC = 28.8% 0.98 0.69, 1.39 0.91 23.8
Capsule formation
B-HCC versus C-HCC 8 [4,26,27,29,30,36,38,39] 1509 B-HCC = 47.7%, C-HCC = 53.8% 0.86 0.57, 1.29 0.46 53.8
B-HCC versus NBNC-HCC 6 [4,26,27,29,38,39] 786 B-HCC = 49.3%, NBNC-HCC = 47.9% 0.96 0.55, 1.67 0.88 51.1
C-HCC versus NBNC-HCC 6 [4,26,27,29,38,39] 725 C-HCC = 52.1%, NBNC-HCC = 47.9% 1.10 0.77, 1.57 0.60 18.9
Serum AFP level (ng/ml)
B-HCC versus C-HCC 9 [3,28-31,33,34,36,41] 1611 B-HCC = 11555.3 ± 45653.8, C-HCC = 2496.0 ± 9014.5 -52.96 -281.61, 175.69 0.65 39.5
B-HCC versus NBNC-HCC 6 [3,28,29,31,33,41] 458 B-HCC = 13927.5 ± 56323.0, NBNC-HCC = 3069.1 ± 9330.6 1385.80 -1099.05, 3870.66 0.27 86.8
C-HCC versus NBNC-HCC 6 [3,28,29,31,33,41] 1064 C-HCC = 2181.0 ± 8052.8, NBNC-HCC = 3069.1 ± 9330.6 -214.61 -714.20, 284.98 0.40 0
Survival
5-year overall survival
B-HCC versus C-HCC 14 [3-5,26-28,30,34-36,38,40-42] 3427 B-HCC = 51.4%, C-HCC = 52.9% 1.00 0.76, 1.31 0.99 61.9
B-HCC versus NBNC-HCC 9 [3-5,26-28,35,38,41] 1289 B-HCC = 50.2%, NBNC-HCC = 53.0% 0.68 0.44, 1.06 0.09 55.8
C-HCC versus NBNC-HCC 9 [3-5,26-28,35,38,41] 1239 C-HCC = 49.0%, NBNC-HCC = 53.0% 0.61 0.33, 1.11 0.10 75.7
5-year disease-free survival
B-HCC versus C-HCC 13 [3,4,26,28-30,34,35,37-41] 2113 B-HCC = 32.3%, C-HCC = 25.5% 1.46 0.88, 2.41 0.14 77.8
B-HCC versus NBNC-HCC 10 [3,4,26,28,29,35,37-39,41] 860 B-HCC = 28.7%, NBNC-HCC = 49.3% 0.39 0.28, 0.53 < 0.001 33.4
C-HCC versus NBNC-HCC 10 [3,4,26,28,29,35,37-39,41] 1245 C-HCC = 26.8%, NBNC-HCC = 49.3% 0.37 0.22, 0.64 < 0.001 69.4
OR = odds ratio; WMD = weighted mean difference; CI = confidence interval; HCC = hepatocellular carcinoma; B-HCC = hepatitis B-related hepatocellular carcinoma; C-HCC = hepatitis C-related hepatocellular
carcinoma; NBNC-HCC = no infection of HBV or HCV related hepatocellular carcinoma; AFP = alpha fetoprotein; ALT = alanine aminotransferase; AST = aspartate aminotransferase; T-Bil = total bilirubin; ICG R15 =
indocyanine green retention rate at 15 minutes.
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0to -8.12, P < 0.001). The prevalence of male sex was
higher in the B-HCC group than in the NBNC-HCC
group (OR: 1.43, 95% CI: 1.10 to 1.86, P =0 . 0 0 8 ) .T h e y
also were more male in the B-HCC group than in the
C-HCC group, although the differences were not statis-
tically significant (P = 0.24).
Liver Function
Serum aspartate aminotransferase and alanine amino-
transferase levels were higher in the C-HCC group than
in the other two groups. The serum total bilirubin level
and indocyanine green retention rate at 15 min were
higher, and the serum albumin level was lower in the C-
HCC group than in the NBNC-HCC group. The platelet
count was higher in the NBNC-HCC group than in the
other two groups. The Child’s grade A was more fre-
quently recognized in the B-HCC group than in the C-
HCC group (Table 2).
Tumor characteristics
The mean tumor size was significantly larger in B-HCC
and NBNC-HCC group than in C-HCC group (respec-
tively: WMD: 1.32, 95% CI: 0.38 to 2.27, P = 0.006;
WMD: -0.86, 95% CI: -1.27 to -0.45, P < 0.001). No sig-
nificant differences were observed between B-HCC and
NBNC-HCC group but NBNC-HCC group tended to
have larger tumors (P = 0.97). The prevalence of liver
cirrhosis was the highest in the C-HCC group, followed
by the B-HCC group, and the NBNC-HCC group (P <
0.01). The incidence of vascular invasion, intrahepatic
metastases/satellite nodules, tumor capsule formation,
and serum AFP level, all were similar in the three
groups (Table 2).
Survival
There was a tendency toward higher 5-year overall sur-
vival rates in the NBNC-HCC group compared to those
in the other two groups, although these differences were
not statistically significant (Table 2).
Pooled analysis of studies furnishing data found that
patients with HBV or HCV infection had a worse 5-year
disease-free survival when compared to patients with
NBNC-HCC (respectively: OR: 0.39, 95% CI: 0.28 to
0.53, P < 0.001; WMD: 0.37, 95% CI: 0.22 to 0.64, P <
0.001) (Figure 1, 2 and 3).
Both the 5-year overall survival and disease-free survi-
v a li nt h eB - H C Ca n dC - H C Cg r o u p sw e r en o ts i g n i f i -
cantly different (Table 2).
Discussion
HBV belongs to a family of DNA viruses called hepad-
naviruses. The oncogenic potential of HBV has been
attributed to its ability to integrate into host cellular
DNA, which, may activate neighboring cellular genes
directly to offer a selective growth advantage to the liver
cells. In addition, production of hepatitis B × (HBx) pro-
tein can act as a transactivator on various cellular genes
for cell growth and tumorigenesis [43]. In contrast,
HCV is a positive-stranded RNA virus the genome of
which does not seem to integrate into hepatocyte’s gen-
ome [44]. Therefore, differences in carcinogenetic
mechanisms between these viruses may affect HCC
characteristics.
Most chronic HBV infections are vertical transmis-
sions during delivery, whereas HCV infections are
known to be blood-borne such as from transfusions and
occurs mainly after the age of 20 years. Consequently,
Figure 1 B-HCC versus C-HCC: Results of the meta-analysis on 5-year disease-free survival. All based on a random-effects meta-analysis.
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than in C-HCC. Interestingly, we also found that the
mean age for patients with NBNC-HCC is significantly
older than the B-HCC group. It is suspected that
NBNC-HCC requires a longer time until it develops
HCC [33]. The liver cirrhosis was more frequently
recognized in the C-HCC group than in the B-HCC and
NBNC-HCC groups. Thus, as reflected by many para-
meters, among the three groups, liver function was the
worst in the C-HCC group.
H C Ci sm o r ep r e v a l e n ti nm e nt h a ni nw o m e n ,t h i s
trend is less apparent for patients with HCC unrelated to
HBV. Both animal and human studies support the impor-
tance of androgen signaling in determining the male pre-
ference of HCC [45]. Increased expression and activation
of androgen receptor (AR) was found in HCC and nontu-
morous liver tissue [46]. A recent study demonstrated that
the HBx protein increased the anchorage-independent col-
ony-formation potency of AR in a nontransformed mouse
hepatocyte cell line. In addition, HBx functioned as a posi-
tive transcriptional coregulator to increase AR-mediated
transcriptional activity [47]. These findings may provide a
plausible explanation for the male gender preference of
HBV-related HCC.
With respect to tumor factors, this study demonstrated
that patients in the NBNC-HCC group had largest
tumors. This was probably due to fewer NBNC-HCC
patients receiving regular follow-up for the liver diseases
since the two major risk factors for HCC, HBV and
HCV, were negative [6,7,33]. The HCC might be
Figure 2 B-HCC versus NBNC-HCC: Results of the meta-analysis on 5-year disease-free survival. All based on a fixed-effects meta-analysis.
Figure 3 C-HCC versus NBNC-HCC: Results of the meta-analysis on 5-year disease-free survival. All based on a random-effects meta-
analysis.
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caused subjective symptoms in the NBNC-HCC patients.
The smaller tumors in the C-HCC group may be
explained by the fact that C-HCC occurring at a much
older age. Older age with possible comorbidities and rela-
tively poor liver function usually preclude C-HCC
patients with larger tumors from undergoing surgery
[42].
In the present study, 5-year disease-free survival rates
were significantly higher in the NBNC-HCC group than
in the B-HCC and C-HCC groups. High rate of intrhepa-
tic recurrence after surgical resection is the main cause
of late death of patients with HCC [48]. According to
point of recurrences time from the date of hepatectomy,
recurrences were classified into early (≤ 2 year) and late
(> 2 year) recurrences [49]. Early recurrences appear to
a r i s em a i n l yf r o mi n t r a h e p a t i cm e t a s t a s e sf r o mr e s i d u e s
of original HCC, whereas late recurrences are more likely
to develop on the basis of underlying liver diseases,
resulting from new carcinogenesis. It is generally
accepted that virus-induced chronic inflammatory necro-
sis and hepatocyte necrosis might cause the hepatocytes
to undergo proliferation and thus increase the occurrence
of genetic aberrations, which may be the main mechan-
ism responsible for late intrahepatic recurrence [49].
Wakai et al. [37] found that the cumulative probability of
intrahepatic recurrence reached a plateau at 2.4 years
after resection in the NBNC group, while it continued to
increase steadily in the hepatitis viral groups. Thus,
improved disease-free survival in the NBNC-HCC group
is attributed to a low incidence of multicentric carcino-
genesis, which is caused by chronic viral attack. In addi-
tion, NBNC patients maintained good liver function
following the initial hepatectomy, and these biological
advantages provided NBNC patients more opportunities
for repeat resection of intrahepatic recurrences, which
may lead to a favorable outcome [38].
Both the 5-year overall survival and disease-free survi-
v a li nt h eB - H C Ca n dC - H C Cg r o u p sw e r en o ts i g n i f i -
cantly different, indicating that influence of the viral
etiology on the outcome of resection surgery in HCC
patients was not obvious.
As a limitation, there are important heterogeneities
between studies. There are many differences between the
studies that serve as sources of heterogeneity, including
variation in surgical skill, variation in perioperative and
postoperative care. The other main source to the hetero-
geneity is NBNC-HCC group and the C-HCC group may
have included patients with HBV. It was demonstrated
that HBV DNA can be detected in the hepatic parench-
yma of many HBsAg-negative HCC patients [50]. How-
ever, the determination of HBV DNA in liver tissue is
not routinely checked during the clinical course of HCC.
Given this heterogeneity, we applied a random effect
model to take between study variation into consideration.
This does not necessarily rule out the effect of heteroge-
neity between studies, but one may expect a very limited
influence. Another limitation is all of data in the present
study comes from observational studies. Observational
studies are subject to a number of biases, including recall
and selection [51]. In addition, since HCC is found com-
monly in China and other parts of South East Asia, most
studies included in current meta-analysis were performed
in Asian patients and the data cannot be extrapolated to
the non- Asian population.
Conclusions
Our meta-analysis showed HCC patients with viral infec-
tion had a poor prognosis compared to patients with
negative serology. It is hypothesized that antiviral thera-
pies would help prevent HCC recurrence by cleaning the
carcinogenic soil and eliminating possibilities of novel
tumorigenesis through their viral suppression and anti-
inflammation action. This theory is supported by a
recently published meta-analysis, in that study postopera-
tive adjuvant antiviral therapy has a significant beneficial
effect after curative treatment of HBV/HCV related HCC
in terms of both survival and tumor recurrence [52].
Thus, for HCC patients with viral infections, postopera-
tive adjuvant antiviral therapy is needed to improve the
outcome.
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